# 

**PB 9 of 2020**

National Health (Originator Brand) Amendment Determination 2020 (No. 1)

*National Health Act 1953*

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the *National Health Act 1953*.

Dated 29 January 2020

**THEA DANIEL**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1 Name of Determination

(1) This Determination is the *National Health (Originator Brand) Amendment Determination 2020 (No. 1).*

(2) This Determination may also be cited as PB 9 of 2020.

2 Commencement

This Determination commences on 1 February 2020.

3 Amendments to PB 100 of 2015

Schedule 1 amends the *National Health (Originator Brand) Determination 2015* (PB 100 of 2015).

Schedule 1 Amendments

(section 3)

[1] Schedule 1, (table item 80)

*Repeal the items:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 80 | Exemestane | Aromasin |  |  |
| 80A | Ezetimibe | Ezetrol |  |  |
| 80B | Ezetimibe and rosuvastatin | Rosuzet Composite Pack |  |  |
| 80C | Ezetimibe with simvastatin | Vytorin |  |  |

*Substitute:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 80 | Exemestane | Aromasin |  |  |
| 80A | Ezetimibe | Ezetrol |  |  |
| 80B | Ezetimibe and rosuvastatin | Rosuzet Composite Pack |  |  |
| 80C | Ezetimibe with atorvastatin | Atozet |  |  |
| 80D | Ezetimibe with simvastatin | Vytorin |  |  |

[2] Schedule 1, (after table item 228)

*Insert:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 228A | Tiotropium | Spiriva  Spiriva Respimat |  |  |